DNA X, Inc. 8-K

What Happened

• DNA X, Inc. (SONM) filed an 8-K on June 4, 2026 announcing that it and Chardan Capital Markets LLC agreed to terminate the ChEF Purchase Agreement and the related Registration Rights Agreement.
• The original ChEF Agreement, entered September 29, 2025, had committed Chardan to purchase, subject to conditions, up to $500 million of the company’s common stock. The agreements were terminated effective 5:00 p.m. New York City time on May 28, 2026, pursuant to a letter agreement dated May 29, 2026.

Key Details

• Parties: DNA X, Inc. and Chardan Capital Markets LLC.
• Original commitment: up to $500 million of common stock under the ChEF Agreement (entered Sept. 29, 2025).
• Termination effective: May 28, 2026 at 5:00 p.m. (NYC time); termination letter dated May 29, 2026.
• The prior filings that contain the full agreement texts were filed as exhibits to the company’s Sept. 29, 2025 Form 8-K.

Why It Matters

• The termination removes a previously disclosed potential source of capital: Chardan is no longer committed to purchase up to $500 million of DNA X shares under that facility.
• For investors, this is a material change to the company’s financing picture; shareholders should review DNA X’s other disclosures for current cash position, financing plans, or potential dilution alternatives.